Virax lodges application to conduct an HIV clinical trial in South Africa
Virax has lodged a Clinical Trial Application (CTA) with the South African Medicines Control Council (MCC) for approval to conduct a Phase I/IIa trial of the VIR201 HIV vaccine. A group of some of South Africa's leading HIV/AIDS clinicians, led by Dr Des Martin, President of the Southern African HIV/AIDS Clinicians Society, has assisted Virax in the development of a VIR201 clinical trial protocol suitable for the prevailing South African environment.
Whilst the MCC review process is conducted, Virax will continue to work with contract research organisation, Quintiles, to prepare suitable clinical trial sites and laboratories to support the trial. It is anticipated that the trial will be conducted in five well established HIV clinics across South Africa.
Significant funding pledges to support the conduct of the trial have been secured from seven international companies with significant business ties in South Africa, with BHP Billiton as the cornerstone contributor. The Company is continuing to complete the total funding of the project. An independent charitable trust has been established to receive the funding, following approval from the MCC for the trial to proceed.
Also, Virax is continuing to prepare an application, for lodgement with the United States Food and Drug Administration, to conduct a Phase II trial of the VIR201 HIV vaccine. Application to other regulatory bodies will follow. The trial is to be conducted in Australia, the US and possibly other countries.
Other news from the department research and development
These products might interest you
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
